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BACKGROUND
Primary hemophagocytic lymphohistiocytosis is a rare syndrome characterized by 
immune dysregulation and hyperinflammation. It typically manifests in infancy 
and is associated with high mortality.
METHODS
We investigated the efficacy and safety of emapalumab (a human anti–interferon-γ 
antibody), administered with dexamethasone, in an open-label, single-group, 
phase 2–3 study involving patients who had received conventional therapy before 
enrollment (previously treated patients) and previously untreated patients who were 
18 years of age or younger and had primary hemophagocytic lymphohistiocytosis. 
The patients could enter a long-term follow-up study until 1 year after allogeneic 
hematopoietic stem-cell transplantation or until 1 year after the last dose of ema-
palumab, if transplantation was not performed. The planned 8-week treatment 
period could be shortened or extended if needed according to the timing of trans-
plantation. The primary efficacy end point was the overall response, which was 
assessed in the previously treated patients according to objective clinical and labo-
ratory criteria.
RESULTS
At the cutoff date of July 20, 2017, a total of 34 patients (27 previously treated 
patients and 7 previously untreated patients) had received emapalumab; 26 pa-
tients completed the study. A total of 63% of the previously treated patients and 
65% of the patients who received an emapalumab infusion had a response; these 
percentages were significantly higher than the prespecified null hypothesis of 40% 
(P = 0.02 and P = 0.005, respectively). In the previously treated group, 70% of the 
patients were able to proceed to transplantation, as were 65% of the patients who 
received emapalumab. At the last observation, 74% of the previously treated patients 
and 71% of the patients who received emapalumab were alive. Emapalumab was 
not associated with any organ toxicity. Severe infections developed in 10 patients 
during emapalumab treatment. Emapalumab was discontinued in 1 patient because 
of disseminated histoplasmosis.
CONCLUSIONS
Emapalumab was an efficacious targeted therapy for patients with primary hemo-
phagocytic lymphohistiocytosis. (Funded by NovImmune and the European Com-
mission; NI-0501-04 and NI-0501-05 ClinicalTrials.gov numbers, NCT01818492 
and NCT02069899.)
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Hemophagocytic lymphohistiocyto-sis is a rare disorder characterized by pathologic immune activation and hyper-
inflammation with deleterious effects on multi-
ple organs.1,2 Primary hemophagocytic lympho-
histiocytosis is a heterogeneous disorder that is 
associated with impaired cytotoxic function of 
natural killer and CD8+ T cells. It typically 
manifests during infancy and is invariably fatal 
if untreated.1,3,4
The objective of treatment for primary hemo-
phagocytic lymphohistiocytosis is to suppress 
inflammation in order to allow for allogeneic 
hematopoietic stem-cell transplantation, the only 
curative therapy for this disease. Various immu-
nochemotherapeutic regimens have been tested.5-7 
No drug has been approved for hemophagocytic 
lymphohistiocytosis, but glucocorticoids and eto-
poside, with or without cyclosporine, investi-
gated by the Histiocyte Society,5,6 have become 
the conventional therapy. Despite the use of in-
creasingly aggressive regimens, no significant 
decrease in mortality (it was approximately 40% 
as of this writing) has been noted over the past 
20 years.5-7 Toxic effects of immunochemother-
apy, particularly myelosuppression and general-
ized immunosuppression, contribute to high 
morbidity and mortality.5,6 Among patients with 
disease f lares, proposed reintensification with 
etoposide8 increases the risk of toxic effects.
No standardized treatment exists for relapsed 
or refractory hemophagocytic lymphohistiocyto-
sis; however, individual case reports involving 
patients who have received biologics and small 
case series involving patients who have received 
alemtuzumab (an anti-CD52 monoclonal anti-
body) and antithymocyte globulin have shown 
efficacy in some patients.9-12 Mounting evidence 
provides support for the pivotal pathogenic role 
of interferon-γ in hemophagocytic lymphohistio-
cytosis. Elevated interferon-γ levels in patients 
with hemophagocytic lymphohistiocytosis corre-
late with active disease,4,13-16 and neutralization 
of interferon-γ in models of hemophagocytic 
lymphohistiocytosis in mice allowed most of the 
mice to survive, reduced signs and symptoms, or 
both.16-20 Targeting other cytokines does not re-
sult in these outcomes.
Emapalumab is a fully human IgG1 anti–
interferon-γ monoclonal antibody that binds free 
and receptor-bound interferon-γ (inhibiting recep-
tor dimerization and transduction of interferon-γ 
signaling) and neutralizes its biologic activity.21 
We prospectively tested the safety and efficacy of 
multiple intravenous doses of emapalumab on a 
background of dexamethasone in patients with 
primary hemophagocytic lymphohistiocytosis.
Me thods
Study Design and Oversight
NI-0501-04 is a phase 2–3, open-label, single-
group study performed at 14 sites in Germany, 
Italy, Spain, the United Kingdom, and the United 
States. The study consisted of screening, an 
8-week treatment period (shortened to 4 weeks 
if donor availability and the patient’s condition 
allowed hematopoietic stem-cell transplantation), 
and a short-term 4-week follow-up. In a long-
term study (NI-0501-05) in which treatment con-
tinued, if needed, as a bridge to transplantation, 
we collected follow-up data until 12 months af-
ter transplantation (see Fig. S1 in the Supple-
mentary Appendix and the study protocol, both 
available with the full text of this article at 
NEJM.org). Results of the combined analysis of 
the NI-0501-04 and NI-0501-05 studies at the 
regulatory cutoff date are presented here.
Approval was obtained from an institutional 
review board or an independent ethics commit-
tee at each center. Written informed consent was 
provided by the patients’ legal representatives. 
The study was designed by the scientific steering 
committee and the sponsor (NovImmune). The 
sponsor was responsible for data gathering and 
management, statistical analysis, and reporting 
of the results. The authors drafted the manu-
script with assistance from medical writers paid 
by the sponsor. All the authors vouch for the 
accuracy and completeness of the data and 
analyses and for the fidelity of the study to the 
protocol.
Patients
Previously treated patients and previously un-
treated male and female patients who were 18 
years of age or younger and who had primary 
hemophagocytic lymphohistiocytosis were includ-
ed. All the patients had active disease at enroll-
ment, and the patients who had received previ-
ous treatment had worsened or reactivated 
disease, had had an unsatisfactory response to 
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conventional therapy, or were unable to continue 
to receive conventional therapy because of ad-
verse effects. Primary hemophagocytic lympho-
histiocytosis was diagnosed on the basis of 
molecular assessment, family history, or the 
presence of five or more of the eight criteria 
proposed by the Histiocyte Society.8
Eligibility criteria are summarized in Table S1. 
Patients with active infections that were poten-
tially associated with interferon-γ neutralization 
(typical or atypical mycobacteria, Histoplasma 
capsulatum, shigella, campylobacter, leishmania, 
or salmonella) were excluded.
Treatment
The starting dose of emapalumab was 1 mg per 
kilogram of body weight every 3 days, and dose 
modifications were initially guided by clinical 
and pharmacokinetic assessments. Subsequently, 
a protocol amendment simplified dose modifi-
cations so that they relied solely on predefined 
clinical and laboratory criteria; after an initial 
dose of 1 mg per kilogram, subsequent doses 
could be increased to 3, 6, and up to 10 mg per 
kilogram (Table S2).
If the patient was not already receiving dexa-
methasone, it was initiated at a dose of 5 to 10 mg 
per square meter of body-surface area per day 
1 day before the administration of emapalumab. 
Cyclosporine could be continued if the patient 
was receiving it before screening, but it could 
not be introduced after the initiation of ema-
palumab. Intrathecal therapy was allowed. After 
the latest protocol amendment, additional treat-
ment for hemophagocytic lymphohistiocytosis 
was permitted after dose escalation of ema-
palumab if the treating physician considered the 
response to be inadequate.
Outcomes
The primary efficacy end point was the overall 
response in previously treated patients at the end 
of treatment in the NI-0501-04 study (Table S3 
and the Statistical Analysis section in the Sup-
plementary Appendix). The overall response 
included the percentage of patients with a com-
plete response, a partial response, or an improve-
ment in measures of hemophagocytic lympho-
histiocytosis. A complete response was defined 
as no fever, a normal spleen size, no cytopenia, 
no hyperferritinemia (defined as a ferritin level 
>2000 ng per milliliter), no evidence of coagu-
lopathy, no neurologic or cerebrospinal f luid 
abnormalities attributable to hemophagocytic 
lymphohistiocytosis, and no sustained increase 
in the level of soluble CD25. A partial response 
was defined as three or more clinical and labo-
ratory abnormalities (including central nervous 
system [CNS] abnormalities) associated with 
hemophagocytic lymphohistiocytosis that met the 
criteria for a complete response. Improvement in 
measures of hemophagocytic lymphohistiocyto-
sis was defined as a change of greater than 50% 
from baseline in at least three clinical and labo-
ratory abnormalities (including CNS involve-
ment) associated with hemophagocytic lympho-
histiocytosis if these values were not normalized.
Secondary efficacy end points (see the Statis-
tical Analysis section in the Supplementary Ap-
pendix) included the time to response, the dura-
tion of response until the end of treatment in the 
NI-0501-04 study, the cumulative duration of 
response until conditioning (or the end of treat-
ment if transplantation was not performed), the 
number of patients in whom the dose of gluco-
corticoids was decreased by at least 50% from 
the baseline dose, the number of patients pro-
ceeding to transplantation, and overall survival, 
including post-transplantation survival and post-
transplantation event-free survival (events of in-
terest were death, graft failure, and relapse of 
hemophagocytic lymphohistiocytosis).
Serum levels of C-X-C motif chemokine ligand 
9 (CXCL9), an interferon-γ–induced chemokine, 
were measured to assess neutralization of inter-
feron-γ (see the Supplementary Appendix). Ad-
verse events, laboratory values, vital signs, and 
the development of antidrug antibodies were 
assessed. The protocol mandated assessment for 
infection (tuberculosis and Epstein–Barr virus, 
cytomegalovirus, and adenovirus infection) once 
weekly for the first 2 weeks and every 2 weeks 
thereafter. During emapalumab treatment, if 
infections were suspected, tests to assess for 
pathogens possibly favored by interferon-γ neu-
tralization were required.
Statistical Analysis
The planned enrollment was 28 previously treat-
ed patients with data that could be evaluated. 
Assuming a response in 70% of the patients, the 
study had 90% power to show a significant im-
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provement over the null hypothesis. The analysis 
populations included the previously treated group 
(patients who had received conventional therapy 
before enrollment), the emapalumab group (all 
patients who received ≥1 infusion of emapalu-
mab) (Table 1), and patients in each group with 
data that could be evaluated.
For the analysis of the primary end point, 
we used an exact binomial test at a two-sided 
alpha level (type I error rate) set at 5% to test 
the null hypothesis that the response would be 
40% or less (see the Supplementary Appendix). 
Summary statistics with the number and per-
centage within each category are presented for 
categorical variables. Results for the evaluation 
of the primary end point were summarized on 
the basis of two-sided exact 95% confidence 
intervals. Kaplan–Meier curves are provided 
with the median time to event and two-sided 
95% confidence intervals for time-to-event 
variables.
The duration of response was defined as the 
total time from the first response to loss of that 
response; response had to be maintained for at 
least 4 days to be considered in the analysis. The 
cumulative duration of response was assessed by 
adding the periods in which patients were “in 
response” and calculating the percentage of days 
“in response” over total treatment days; no re-
sponse was assigned a value of 0 days.
Safety analyses were performed separately for 
the periods before and after conditioning. Data 
for patients who did not undergo transplantation 
by the cutoff date were analyzed as part of the 
preconditioning period. The association between 
the response and CXCL9 levels at the end of 
treatment was assessed by means of logistic-
regression analysis.





Patients Who Received 
 Emapalumab 
(N = 34)
Age at written informed consent — yr†
Mean 2.55±3.23 2.24±2.99
Median (range) 1.00 (0.2–13.0) 1.00 (0.1–13.0)
Sex — no. (%)
Female 16 (59) 18 (53)
Male 11 (41) 16 (47)
Age at diagnosis of hemophagocytic lymphohistiocytosis — yr
Mean 2.32±3.43 2.09±3.16
Median (range) 0.91 (0.03–13.81) 0.85 (0.03–13.81)
Genetic confirmation of diagnosis — no. (%) 22 (81) 27 (79)
Gene
FHL1 0 2 (6)
FHL2  5 (19)  7 (21)
FHL3  7 (26)  8 (24)
FHL4 1 (4) 1 (3)
FHL5 2 (7) 2 (6)
Griscelli’s syndrome type 2  5 (19)  5 (15)
X-linked lymphoproliferative disorder
Type 1 1 (4) 1 (3)
Type 2 1 (4) 1 (3)
*  Plus–minus values are means ±SD.
†  Consent was obtained from the patients’ legal guardians.
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R esult s
Study Population
A total of 53 patients underwent screening, and 
34 patients (27 previously treated patients and 
7 previously untreated patients) received ema-
palumab. A total of 26 patients (76%) completed 
the NI-0501-04 study and 8 (24%) discontinued 
the study prematurely. A total of 28 patients (82%) 
entered long-term follow-up (Fig. S2).
Patients had characteristics that were consis-
tent with the primary hemophagocytic lympho-
histiocytosis population, and early disease onset 
and a mutation known to cause primary hemo-
phagocytic lymphohistiocytosis were identified 
in the majority of patients (79%) (Table 1). The 
median age at study entry was 1.0 year (range, 
0.1 to 13.0), and all the signs and symptoms of 
hemophagocytic lymphohistiocytosis were present 
(Table 1 and Table S4). Previous conventional 
therapy included dexamethasone and etoposide 
in the majority of patients. During emapalumab 
treatment, intrathecal therapy (glucocorticoids, 
methotrexate, or both) was administered to 12 
patients (as continuation of previous therapy in 
11 patients). Five patients who were receiving 
cyclosporine before study entry continued to re-
ceive it. Three patients received concomitant eto-
poside, alemtuzumab, or both in the NI-0501-04 
study. Five other patients received etoposide while 
they continued to receive emapalumab in the 
NI-0501-05 study because of an unsatisfactory 
response (Table S5).
Efficacy
At the protocol-specified end of treatment (8 
weeks), 63% of the previously treated patients 
(two-sided 95% confidence interval [CI], 42 to 
81) and 65% of the patients who received ema-
palumab (two-sided 95% CI, 46 to 80) had had a 
response (Fig. 1A and Table S6). The confidence 
limit for the response in each group was higher 
than the prespecified null hypothesis of 40% 
(P = 0.02 and P = 0.005 for the comparison in the 
two groups, respectively). Among previously treat-
ed patients, 26% had a complete response, 30% 
had a partial response, and 7% had improve-
ment in measures of hemophagocytic lympho-
histiocytosis; these responses among patients 
who received emapalumab were 21%, 32%, and 
12%, respectively (Fig. 1A). The response was 
also assessed at the end of treatment indepen-
dently of whether it occurred up to or after 8 weeks 
(the protocol-specified end of treatment) (Fig. 1B). 
Of the 12 patients with CNS involvement, CNS 
disease normalized in 6, improved in 4, and 
could not be evaluated in 2 because of worsen-
ing hemophagocytic lymphohistiocytosis (see the 
Supplementary Appendix).
During emapalumab treatment, CXCL9 levels 
rapidly and markedly decreased (median, 30% of 
the baseline level on day 5) (Fig. S5). Logistic-
regression analysis indicated that low CXCL9 
levels were associated with a response at the end 
of treatment (Fig. 1C); these findings provided 
support for neutralization of interferon-γ as a 
relevant therapeutic objective in patients with 
primary hemophagocytic lymphohistiocytosis.
Dexamethasone was administered at a median 
daily dose of 10 mg per square meter of body-
surface area at baseline and tapered by at least 
50% at 8 weeks in 44% of the previously treated 
patients and in 47% of the patients who received 
emapalumab. In addition, the dose of dexa-
methasone was reduced by 30 to 49% in 18% 
and 15% of the patients, respectively.
The median time to response was 8 days 
(95% CI, 7 to 14) in the previously treated pa-
tients and 8 days (95% CI, 5 to 10) in the patients 
who received emapalumab. The first response 
was maintained for 18 days in 75% of the previ-
ously treated patients and for 26 days in 75% of 
the patients who received emapalumab (Fig. S3). 
Four patients who received emapalumab (of whom 
three had been previously treated) were not in-
cluded in this analysis because they did not have 
a response. The median cumulative durations of 
response to conditioning were 31.0 days and 
33.5 days in the previously treated patients and 
the patients who received emapalumab, respec-
tively, which represented 75.4% (interquartile 
range, 31 to 91) and 75.7% (interquartile range, 
33 to 91) of treatment time, respectively. Fig-
ure 2A and 2B shows plots of responses in indi-
vidual patients from the beginning of treatment 
to the initiation of conditioning.
In the previously treated group, 19 patients 
(70%) proceeded to hematopoietic stem-cell trans-
plantation. A total of 47% of these patients re-
ceived myeloablative conditioning, and 53% 
received reduced-intensity conditioning. In the 
emapalumab group, 22 patients (65%) proceeded 
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to transplantation (half received myeloablative 
conditioning, and half received reduced-intensity 
conditioning). Two patients had sustained con-
trol of hemophagocytic lymphohistiocytosis up 
to 12 months after completion of emapalumab 
treatment; they did not undergo transplantation 
because of their physicians’ assessment.
Survival to transplantation and overall sur-
vival are shown in Figure 3. At the last observa-
tion, 20 of 27 patients (74%) in the previously 
treated group were alive with an estimated prob-
ability of survival of 73.4% (95% CI, 52.2 to 86.4) 
at 12 months. The corresponding values for the 
emapalumab group were 24 of 34 patients (71%) 
and 69.3% (95% CI, 50.3 to 82.2).
The estimated probability of survival after 
transplantation at 12 months was 89.5% (95% 
CI, 64.1 to 97.3) among previously treated pa-
tients and 90.2% (95% CI, 66.2 to 97.5) among 
patients who received emapalumab. A total of 18 
patients did not have an event up to 12 months 
after transplantation (Fig. S4); complete donor 
chimerism was observed in all but 1 surviving 
patient at 1 year of follow-up (data were missing 
for 1 patient).
Figure 1. Percentages of Patients with an Overall 
 Response (Complete Response, Partial Response,  
or Improvement in Measures of Hemophagocytic 
 Lymphohistiocytosis).
Panel A shows the percentages of patients with a com-
plete response, a partial response, or improvement in 
measures of hemophagocytic lymphohistiocytosis at 
the end of 8 weeks (the end of the NI-0501-04 study) 
among the previously treated patients and among the 
patients who received emapalumab. For patients who 
completed treatment or discontinued treatment before 
8 weeks, the end of the study was 3 days after the last 
emapalumab infusion. Panel B shows the response 
among the patients at the end of treatment overall 
(i.e., 3 days after the last emapalumab infusion, regard-
less of whether it occurred before, at, or after 8 weeks 
[16 patients continued to receive emapalumab after  
8 weeks in the long-term follow-up study]). Panel C 
shows the predicted probability of a clinical response 
at the end of treatment as a function of log10-trans-
formed levels of C-X-C motif chemokine ligand 9 (CXCL9) 
at the end of treatment. The gray area indicates the 
pointwise 95% confidence intervals for the null hypoth-
esis of no association, and the black dots indicate the 
actual observed clinical responses (on a scale from  
0 to 1, with 0 indicating no response and 1 indicating  
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Safety
Safety results are presented up to the 12-month 
follow-up. Median durations of emapalumab ad-
ministration were 48 days (range, 4 to 157) in the 
previously treated patients and 59 days (range, 4 to 
245) in the patients who received emapalumab.
All the patients had at least one adverse event 
during the preconditioning or postconditioning 
Figure 2. Response Status in Individual Patients over Time.
Swimmer plots show the response status in previously treated patients (Panel A) and previously untreated patients 
(Panel B) from the day of the first emapalumab infusion (study day 0) until the start of conditioning. Swimmer plots 
were constructed by deriving response status according to the overall response rate algorithm on each day of treatment. 
The response was considered to be lost on the days when the criteria for an improvement in measures of hemophagocyt-
ic lymphohistiocytosis were not met. If a measurement needed for the response assessment was missing, the mid-
point approach was used to estimate the missing value. Patient 16-09 discontinued emapalumab during the study 
because of the administration of other therapies for hemophagocytic lymphohistiocytosis; this was a withdrawal cri-
terion in the version of the protocol that was current at that time. The patient received alemtuzumab and etoposide 
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periods (Table 2 and Table S7). Ten patients who 
received emapalumab died (eight before trans-
plantation and two after transplantation) (Table 
S8). None of the deaths were considered by the 
investigators to be related to emapalumab. 
Causes of death included multiorgan failure (in 
three patients, including one with septic shock), 
respiratory failure (in two patients), and gastro-
intestinal hemorrhage, acute respiratory distress 
syndrome (ARDS), circulatory collapse associat-
ed with ARDS, refractory hemophagocytic lym-
phohistiocytosis, and neurologic deterioration 
(in one patient each). In addition, after trans-
plantation and after the cutoff date, one patient 
died from cytomegalovirus pneumonia.
A total of 35% of the patients entered the 
study with either an ongoing infection or posi-
tive microbiologic tests. During emapalumab 
treatment and before conditioning, 13 infections 
were reported as serious adverse events, of which 
8 were severe (Table S9). All the infections re-
solved except for 1 case of fatal septic shock that 
occurred after the second emapalumab infusion. 
Fifteen infections were reported as serious ad-
verse events after conditioning, and 4 were as-
sessed as being severe. Three infections occurred 
in two patients with severe complications of 
transplantation (graft-versus-host disease and 
graft failure in one patient each); both patients 
died. The fourth infection occurred 4 weeks after 
Figure 3. Kaplan–Meier Estimates of Survival.
Shown are estimates of the probability of survival until HSCT and estimates of the probability of overall survival among the previously 
treated patients and among patients who received emapalumab. One previously untreated patient died after HSCT after the regulatory 
cutoff date and was not included in the analyses. At 8 weeks, there were three deaths among the previously treated patients and one 
death among the previously untreated patients, all before HSCT. At 12 weeks, there were four deaths among the previously treated pa-
tients and one death among the previously untreated patients, all before HSCT. At 6 months, there were five deaths among the previously 
treated and two deaths among the previously untreated patients before HSCT; there were two deaths among the previously treated pa-
tients after HSCT. At 12 months, there were five deaths among the previously treated patients and three deaths (one during conditioning) 
among the previously untreated patients before HSCT; two of the previously treated patients died after HSCT. After HSCT, one patient 
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transplantation and resolved. One case of dis-
seminated histoplasmosis and one case of nec-
rotizing fasciitis were reported by the investi-
gators as being related to emapalumab.
No clinically significant changes noted in 
hematologic findings, clinical laboratory values, 
hepatic or renal function, urinalysis results, or 
vital signs were attributed by the investigators to 
emapalumab. Signs of myelosuppression related 
to emapalumab did not develop in any of the 
patients. The adverse-event profile was not ap-
preciably different in patients who received 
additional treatment for hemophagocytic lym-
phohistiocytosis and in those who received 
emapalumab only, probably because of the small 
sample size and the few and often reduced 
doses of the additional treatments for hemo-
phagocytic lymphohistiocytosis.
Antidrug antibodies were detected in one 
patient. No related adverse events (in particu-
lar, no hypersensitivity reaction) occurred when 
the antibodies were detected, and the pharma-
Table 2. Adverse Events.*






 (N = 34)
After Conditioning 
(N = 23)
number of patients (percent)
At least one adverse event 26 (96) 19 (100) 32 (94) 23 (100)
At least one adverse event related to study 
drug
8 (30) 0 10 (29) 1 (4)
At least one adverse event leading to 
withdrawal from the study or dis-
continuation of the study drug
2 (7) 0 2 (6) 0
At least one serious adverse event 17 (63) 13 (68) 21 (62) 15 (65)
At least one serious adverse event related to 
study drug
2 (7) 0 2 (6) 0
Infection
Reported as adverse event 16 (59) 15 (79) 19 (56) 16 (70)
At least one reported as serious adverse 
event
8 (30) 8 (42) 11 (32) 8 (35)
Aggravated condition†
Reported as adverse event 12 (44) 2 (11) 17 (50) 3 (13)
At least one reported as serious adverse 
event
3 (11) 1 (5) 5 (15) 2 (9)
Infusion reactions
Total 7 (26) 0 9 (26) 0
At least one reported as serious adverse 
event
0 0 0 0
Death
Total 5 (19) 2 (11) 8 (24) 2 (9)
At least one serious adverse event leading 
to death
4 (15)‡ 2 (11) 7 (21)‡ 2 (9)
*  The period before conditioning refers to the time between the initiation of emapalumab treatment and the day before the initiation of the 
conditioning regimen. The period after conditioning refers to the time between the initiation of conditioning and the last available observation.
†  An aggravated condition is a reactivation, flare, or worsening of hemophagocytic lymphohistiocytosis. Twenty-five such events occurred in 
17 patients who received emapalumab: 21 resolved, 1 improved, and 3 did not resolve. Among these 3 patients, 1 patient who received eto-
poside, alemtuzumab, and antithymocyte globulin had an aggravated condition that did not resolve, 1 patient who received one dose  
of alemtuzumab and one dose of etoposide had an aggravated condition that did not resolve, and 1 patient transferred to palliative care 
because of a preexisting neurologic coexisting condition and acute neurologic deterioration.
‡  One patient died after withdrawal of treatment; this patient was not reported to have an event with a fatal outcome.
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cokinetic properties of emapalumab were un-
changed.
Discussion
In this study, neutralizing interferon-γ and con-
trolling hyperinflammation with emapalumab 
were efficacious in previously treated children 
with primary hemophagocytic lymphohistiocy-
tosis. Most patients carried mutations known to 
cause hemophagocytic lymphohistiocytosis and 
were in poor health, and conventional therapy for 
hemophagocytic lymphohistiocytosis had failed 
to control the disease. In the studies conducted 
by the Histiocyte Society involving newly diag-
nosed patients with primary hemophagocytic 
lymphohistiocytosis (HLH-94 and HLH-2004),5,6 
the percentages of patients with a response at 
2 months, as subjectively assessed by treating 
physicians, were 59% and 51%, respectively. In 
our study, the percentage of previously treated 
patients with a response, as assessed by objective 
clinical and laboratory criteria, was 63%. Only 
seven previously untreated patients received 
emapalumab; more patients must be evaluated 
before conclusions can be drawn about the ef-
ficacy of emapalumab in this group.
During emapalumab treatment, improvement 
in measures of hemophagocytic lymphohistiocy-
tosis followed the same temporal pattern as the 
decrease in serum levels of CXCL9, a chemokine 
exclusively induced by interferon-γ22 and hence a 
measure of interferon-γ neutralization. Logistic-
regression analysis indicated an association be-
tween the probability of a response and a de-
crease in the CXCL9 level at 8 weeks; this 
suggests that neutralization of interferon-γ is a 
relevant therapeutic objective in primary hemo-
phagocytic lymphohistiocytosis.
Primary hemophagocytic lymphohistiocytosis 
is a highly unstable disease with frequent reac-
tivations. In this study, frequent assessment of 
disease measures allowed determination of the 
time during which patients had a response until 
conditioning (or 8 weeks for patients who did 
not undergo transplantation). The median cumu-
lative duration of response was 75% of days 
until transplantation. The frequent dosing (rela-
tive to other monoclonal antibodies) and dose 
adjustment based on clinical and laboratory 
values may have led to an increase in the dura-
tion of response.
Patients with primary hemophagocytic lympho-
histiocytosis are quite ill, with a variety of dis-
ease manifestations. Emapalumab did not appear 
to amplify the adverse events associated with the 
disease. Most adverse events were mild and at-
tributable to reactivation or worsening of hemo-
phagocytic lymphohistiocytosis, coexisting condi-
tions, toxic effects of coadministered drugs, or all 
of these variables. With the exclusion of infusion-
related reactions, only two serious adverse events 
related to emapalumab were reported; data to 
confirm this initial favorable profile are lacking. 
No reductions in the dose of emapalumab were 
implemented. Treatment was discontinued in one 
patient with disseminated histoplasmosis. No 
premedication was required for emapalumab in-
fusions. The patients who received emapalumab 
did not have myelosuppression, which is typi-
cally observed with conventional etoposide-based 
therapy and, together with organ toxicity, results 
in frequent dose reductions and discontinua-
tions.6 The administration of emapalumab per-
mitted dexamethasone tapering.
As expected in this population,2,5,6 one third 
of the patients had an infection at the beginning 
of the study. Infections also occurred frequently 
during the study and were usually associated 
with disease flares. Infectious episodes resolved 
with antimicrobial therapy within the expected 
time period. The absence of interferon-γ bio-
logic activity might lead to increased susceptibil-
ity to specific infections.23-26
Most patients who received emapalumab in 
our study proceeded to allogeneic hematopoietic 
stem-cell transplantation. The outcomes in pa-
tients who underwent transplantation compared 
favorably with those reported previously with 
either myeloablative or reduced-intensity condi-
tioning regimens.27,28 This may be related to the 
ability to decrease doses of glucocorticoids and 
prevent toxic effects associated with conven-
tional therapies for hemophagocytic lymphohis-
tiocytosis. Two patients (without a confirmed 
genetic diagnosis) did not have an HLA-compat-
ible donor and did not undergo transplantation 
by the end of the study follow-up period; hemo-
phagocytic lymphohistiocytosis resolved in these 
patients, and they survived.
The use of additional therapies for hemophago-
cytic lymphohistiocytosis was allowed in patients 
who had an insufficient response to emapalumab, 
given the dismal prognosis in young patients in 
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whom multiple lines of therapy fail. No safety 
concerns were raised because of concomitant 
administration of therapies. Although a clinical-
ly meaningful improvement in disease control 
was not observed in the limited number of pa-
tients who received additional treatments, the 
addition of conventional agents to emapalumab 
remains an option in patients with hemophago-
cytic lymphohistiocytosis that is difficult to treat, 
and it may permit the use of lower doses of 
conventional agents, shorter durations of treat-
ment with these agents, or both.
In conclusion, in this study, emapalumab was 
effective with a low level of toxic effects in pa-
tients with primary hemophagocytic lymphohis-
tiocytosis. The study provides support for fur-
ther investigation of emapalumab in patients with 
secondary forms of hemophagocytic lymphohis-
tiocytosis in whom interferon-γ has been sug-
gested to be pathogenic.14
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